.Pharmacolibrary.Drugs.ATC.J.J01FA01

Information

Erythromycin is a macrolide antibiotic used primarily for the treatment of respiratory tract infections, skin infections, and some sexually transmitted infections. It is active against many Gram-positive bacteria and some Gram-negative bacteria. Erythromycin is approved and still used clinically, although its use has declined with the introduction of newer macrolides.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after a single oral dose of erythromycin base.

References

1. Bizjak, ED, & Mauro, VF (1997). Digoxin-macrolide drug interaction. The Annals of pharmacotherapy 31(9) 1077–1079. DOI:10.1177/106002809703100918 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9296249

2. Yu, KS, et al., & Shin, SG (2001). Ethnic differences and relationships in the oral pharmacokinetics of nifedipine and erythromycin. Clinical pharmacology and therapeutics 70(3) 228–236. DOI:10.1067/mcp.2001.117703 PUBMED:https://pubmed.ncbi.nlm.nih.gov/11557910

3. Hall, KW, et al., & DiSanto, AR (1982). Pharmacokinetics of erythromycin in normal and alcoholic liver disease subjects. Journal of clinical pharmacology 22(7) 321–325. DOI:10.1002/j.1552-4604.1982.tb02682.x PUBMED:https://pubmed.ncbi.nlm.nih.gov/7107981

Revisions

• 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)